中文

Hong Kong Stocks · Free Data Page

SIMCERE PHARMA 02096

SIMCERE PHARMA: FY2025 revenue CN¥7.73B (+16.50% YoY); net income CN¥1.34B; 0 alerts, 1 watch item out of 17 risk checks; TTM dividend HK$0.21/sh.
Close PriceHK$10.77Day +5.80%Market CapHK$27.66BP/E15.5xTTMP/B2.55xDividend Yield1.94%TTMROE (FY2025)16.2%Avg. equity

Prices are closing data as of 2026-11-04, not real-time quotes. HK P/E and P/B multiples come from Eastmoney HK key statistics. Metric definitions: P/E, P/B, ROE.

Want the full AI research report for SIMCERE PHARMA?

This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.

New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.

10-Year FinancialsFY2017–2025

Financial statements are reported in CNY, while share price and market cap are quoted in HKD.

Key Multi-Year Facts

  • Revenue moved from CN¥3.87B in FY2017 to CN¥7.73B in FY2025 (8-year CAGR +9.0%).
  • Profitable in every fiscal year across 2017–2025.
  • Operating cash flow was below half of net income in FY2020, FY2021, FY2023.

Latest 5 Fiscal Years

Fiscal Year20212022202320242025
Revenue (CNY B)5.006.326.616.647.73
YoY10.9%26.5%4.5%0.4%16.5%
Net Income (CNY B)1.510.930.710.721.34
YoY125.1%-38.2%-23.2%1.0%86.2%
Operating Cash Flow (CNY B)-0.201.350.151.392.01
ROE23.4%13.7%10.0%10.1%16.2%
Gross Margin78.4%79.0%75.4%80.2%81.6%
Net Margin30.1%14.7%10.8%10.9%17.4%
Debt-to-Assets36.4%33.7%33.5%38.5%36.1%
Show all 9 fiscal years
Fiscal Year201720182019202020212022202320242025
Revenue (CNY B)3.874.515.044.515.006.326.616.647.73
YoY—16.7%11.6%-10.5%10.9%26.5%4.5%0.4%16.5%
Net Income (CNY B)0.350.731.000.671.510.930.710.721.34
YoY—109.4%36.8%-33.3%125.1%-38.2%-23.2%1.0%86.2%
Operating Cash Flow (CNY B)0.940.780.770.10-0.201.350.151.392.01
ROE19.7%43.9%65.9%—23.4%13.7%10.0%10.1%16.2%
Gross Margin84.8%82.9%82.4%80.0%78.4%79.0%75.4%80.2%81.6%
Net Margin9.1%16.3%19.9%14.8%30.1%14.7%10.8%10.9%17.4%
Debt-to-Assets65.7%75.3%78.1%—36.4%33.7%33.5%38.5%36.1%

Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: HKEX / Eastmoney financial statements, compiled mechanically without AI. Official filings

Risk ChecklistAs of 2026-11-05

Rules-based screening using HK financial statements and HKEX announcement categories (no AI opinions).

0Alert 1Watch 16Pass

Items Flagged for Review

  • Watch

    Profit WarningMaterial Events

An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.

Dividends

Trailing 12-month dividend: HK$0.209 per share, or 1.94% yield at closing price; last full fiscal year: HK$0.209 (payout ratio 30.1%).

Figures are gross HKD per share before applicable withholding or Stock Connect dividend taxes.

More data: All research reports · Sector leaders · Market hours & holidays.

Compiled mechanically from public filings and market quotes (data as of 2026-11-05). For informational purposes only, not investment advice.